Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
维生素D相关/核受体
内分泌学/激素
/ 甲状腺激素受体 / L-Thyroxine sodium/左甲状腺素钠

L-Thyroxine sodium/左甲状腺素钠 {[allProObj[0].p_purity_real_show]}

货号：A208207 同义名： 左旋甲状腺素钠 / T4 sodium; Levothyroxine sodium

L-Thyroxine sodium 是一种合成甲状腺激素，可通过 DIO 酶转化为活性三碘甲状腺氨酸（T3），用于甲状腺功能减退的研究。

L-Thyroxine sodium/左甲状腺素钠 化学结构 CAS号：55-03-8
L-Thyroxine sodium/左甲状腺素钠 化学结构
CAS号：55-03-8
L-Thyroxine sodium/左甲状腺素钠 3D分子结构
CAS号：55-03-8
L-Thyroxine sodium/左甲状腺素钠 化学结构 CAS号：55-03-8
L-Thyroxine sodium/左甲状腺素钠 3D分子结构 CAS号：55-03-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

L-Thyroxine sodium/左甲状腺素钠 纯度/质量文件 产品仅供科研

货号：A208207 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

L-Thyroxine sodium/左甲状腺素钠 生物活性

描述 L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism[3]. The topic of pharmacological interference on L-T4 (L-thyroxine) therapy addresses the patient with primary hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the biochemical target[4]. Compared with L-T4 alone, replacement therapy with the combination of L-T4+L-T3 (L-triiodothyronine) shows favourable changes in serum lipid profile, but higher activation of bone resorption[5]. Standard L-thyroxine supplementation in HT (Hashimoto's thyroiditis) patients exerted significant immunoregulatory effects, associated with quantitative and phenotypic changes of peripheral blood DC (dendritic cells) subpopulations[6]. The thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism[7].

L-Thyroxine sodium/左甲状腺素钠 细胞实验

Cell Line
Concentration Treated Time Description References
white pre-adipocytes 100 nM 48 hours To investigate the effect of T3 on UCP1 expression in Mkk6−/− white adipocytes, results showed that Mkk6−/− adipocytes were more sensitive to TH stimulation, expressing higher levels of UCP1 than WT cells. Nat Commun. 2017 Oct 11;8(1):856

L-Thyroxine sodium/左甲状腺素钠 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced obesity model Subcutaneous injection 400 µg/kg 5 consecutive days To study the role of A-FABP in the conversion of T4 to T3, results showed that A-FABP-deficient mice had reduced energy expenditure after cold stress or high-fat diet, which could be reversed by recombinant A-FABP infusion. Nat Commun. 2017 Jan 27;8:14147
Male mice ATRX-deficient mice Subcutaneous injection 0.1 mg/kg Daily injections from P0 to P14 Partially restored myelination deficits in ATRX-deficient mice Nat Commun. 2023 Nov 4;14(1):7090

L-Thyroxine sodium/左甲状腺素钠 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03693612 Neoplasms Phase 1 Phase 2 Recruiting June 16, 2022 United States, Massachusetts ... 展开 >> GSK Investigational Site Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, New York GSK Investigational Site Not yet recruiting New York, New York, United States, 10016- Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting New York, New York, United States, 10032 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Oklahoma GSK Investigational Site Not yet recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Pennsylvania GSK Investigational Site Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Texas GSK Investigational Site Recruiting San Antonio, Texas, United States, 78240 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Principal Investigator: Anthony Tolcher          Australia, New South Wales GSK Investigational Site Not yet recruiting Darlinghurst, New South Wales, Australia, 2010 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Australia, Victoria GSK Investigational Site Not yet recruiting Melbourne, Victoria, Australia, 3000 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Canada, Ontario GSK Investigational Site Not yet recruiting Ottawa, Ontario, Canada, K1H 8L Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Toronto, Ontario, Canada, M5G 2M Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com 收起 <<
NCT00945282 Infection, Human Immunodeficie... 展开 >>ncy Virus 收起 << Phase 2 Completed - Argentina ... 展开 >> GSK Investigational Site Buenos Aires, Argentina, B1602DBG 收起 <<
NCT02705807 Cardiovascular Disease Phase 4 Completed - Japan ... 展开 >> GSK Investigational Site Okayama, Japan, 701-1192 收起 <<

L-Thyroxine sodium/左甲状腺素钠 参考文献

[1]Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes. 2003 Dec;111(8):455-70.

[2]Nilsson SF, Peterson PA. Studies on thyroid hormone-binding proteins. I. The subunit structure of human thyroxine-binding globulin and its interaction with ligands. J Biol Chem. 1975 Nov 10;250(21):8543-53.

[3]Arici M, Oztas E, Yanar F, Aksakal N, Ozcinar B, Ozhan G. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323

[4]Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents. Front Endocrinol (Lausanne). 2020 Dec 22;11:607446

[5]Fadeyev VV, Morgunova TB, Melnichenko GA, Dedov II. Combined therapy with L-thyroxine and L-triiodothyronine compared to L-thyroxine alone in the treatment of primary hypothyroidism. Hormones (Athens). 2010 Jul-Sep;9(3):245-52

[6]Stasiolek M, Dedecjus M, Adamczewski Z, Sliwka PW, Brzezinski J, Lewinski A. Effect of L-thyroxine treatment on peripheral blood dendritic cell subpopulations in patients with Hashimoto's thyroiditis. Folia Histochem Cytobiol. 2014;52(2):138-43

[7]Kweon KH, Park BH, Cho CG. The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci. 2007 Feb;22(1):114-6

L-Thyroxine sodium/左甲状腺素钠 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.25mL

0.25mL

0.13mL

6.26mL

1.25mL

0.63mL

12.52mL

2.50mL

1.25mL

L-Thyroxine sodium/左甲状腺素钠 技术信息

CAS号55-03-8
分子式C15H10I4NNaO4
分子量 798.85
SMILES Code N[C@@H](CC1=CC(I)=C(C(I)=C1)OC2=CC(I)=C(C(I)=C2)O)C([O-])=O.[Na+]
MDL No. MFCD00002596
别名 左旋甲状腺素钠 ;T4 sodium; Levothyroxine sodium; L-T4 sodium; L-Thyroxine(sodium)
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, room temperature
溶解方案

DMSO: 60 mg/mL(75.11 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 14 mg/mL(17.53 mM)，配合低频超声，并调节pH至11

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二

Tags: L-Thyroxine | 55-03-8 | Levothyroxine | T4 | T 4 | T-4 | Vitamin D Related/Nuclear Receptor | Metabolic Enzyme/Protease | Thyroid Hormone Receptor | Endogenous Metabolite | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | L-Thyroxine sodium/左甲状腺素钠 纯度/质量文件 | L-Thyroxine sodium/左甲状腺素钠 生物活性 | L-Thyroxine sodium/左甲状腺素钠 临床数据 | L-Thyroxine sodium/左甲状腺素钠 参考文献 | L-Thyroxine sodium/左甲状腺素钠 实验方案 | L-Thyroxine sodium/左甲状腺素钠 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z